<--- Back to Details
First PageDocument Content
Pharmaceuticals policy / Pharmaceutical industry / Clinical research / Flunixin / Food and Drug Administration / Abbreviated New Drug Application / Approved drug / Non-steroidal anti-inflammatory drug / Animal drugs / Pharmaceutical sciences / Pharmacology / Medicine
Date: 2009-12-18 12:36:37
Pharmaceuticals policy
Pharmaceutical industry
Clinical research
Flunixin
Food and Drug Administration
Abbreviated New Drug Application
Approved drug
Non-steroidal anti-inflammatory drug
Animal drugs
Pharmaceutical sciences
Pharmacology
Medicine

Microsoft Word - FARAD Newsletter #13

Add to Reading List

Source URL: www.farad.org

Download Document from Source Website

File Size: 259,46 KB

Share Document on Facebook

Similar Documents

The EVMS Autism Spectrum Disorder Program was started by Maria Urbano, M.D., and Kathrin Hartmann, Ph.D., in 2010 to provide clinical services, research, and community outreach to individuals and their families for Autis

DocID: 1vrwY - View Document

Towards a Composite Clinical Endpoint: Identifying a Core Set of Patient and Caregiver Relevant Outcome Measures Through Qualitative Research on the Global Impact of Dravet Syndrome Rima Nabbout1, Stephane Auvin2, Cather

DocID: 1vpIt - View Document

Clinical Research Registration at Public Registry

DocID: 1vnxr - View Document

Grattoni Alessandro, Ph.D. Chairman, The Department of Nanomedicine, The Houston Methodist Research Institute, Houston, Texas (USA) Dr. Grattoni’s research is dedicated to the development and clinical translation of im

DocID: 1vi9N - View Document

Clinical & Translational Research 101 Thursday, August 10, 2017 Time Location

DocID: 1vglz - View Document